Nonsteroidal anti-inflammatory drug metabolism potentiates interferon alfa signaling by increasing STAT1 phosphorylation

Hepatology

Volumn 30, Issue 2, 1999, Pages 510-516

  Giambartolomei, Stefania ^a   Artini, Marco ^a,b   Almerighi, Cristiana ^b   Moavero, Sabrina Maria ^b   Levrero, Massimo ^b   Balsano, Clara ^a,b,c  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c POLICLINICO UMBERTO I   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; ARACHIDONIC ACID; INDOMETACIN; STAT1 PROTEIN;

ARACHIDONIC ACID METABOLISM; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG METABOLISM; DRUG POTENTIATION; GENE ACTIVATION; HEPATITIS C; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONIC ACID; CYCLOOXYGENASE INHIBITORS; DNA-BINDING PROTEINS; HUMANS; INDOMETHACIN; INTERFERON-ALPHA; PHOSPHOLIPASES A; PHOSPHORYLATION; RESPONSE ELEMENTS; STAT1 TRANSCRIPTION FACTOR; TRANS-ACTIVATION (GENETICS); TRANS-ACTIVATORS; TUMOR CELLS, CULTURED;

EID: 0032811406     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510300224     Document Type: Article

References (26)

1. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. HEPATOLOGY 1996;24:778-789.
2. Pagliaro L, Craxì A, Cammà C, Tinè F, Di Marco V, Lo Iacono O, Almasio P. Interferon-α for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. HEPATOLOGY 1994;19:821-828.
3. National Institutes of Health Consensus Development Conference Panel Statement: management of hepatitis C. HEPATOLOGY 1997;26:2S-10S.
4. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-356.
5. Reichard O, Schvarcz R, Weiland O. Therapy of hepatitis C: alpha interferon and ribavirin. HEPATOLOGY 1997;26:108S-111S.
6. Brillanti S, Foli M, Gramantieri L, Di Tomaso M, Masci C, Bolondi L. Triple antiviral therapy for chronic hepatitis C in interferon alfa non-responder: a pilot randomized controlled study. HEPATOLOGY 1997;4(Supp):367A.
7. Angelico M, Gaudin C, Pescarmona E, Rapicetta M, Del Vecchio C, Bini A, Spada E, et al. Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up. Am J Gastroenterol 1995;90:263-269.
8. Andreone P, Cursaro G, Gasbarrini G. Interferon alpha therapy combined with nonsteroid anti-inflammatory drugs for treatment of chronic viral hepatitis? HEPATOLOGY 1992;16:505.
9. Bryan R, Williams G, Haque JS. Interacting pathways of interferon signaling. Semin Oncol 1997;24:70-77.
10. Bhattacharya S, Eckner R, Grossman S, Oldread E, Arany Z, D'Andrea A, Livingston DM. Cooperation of STAT-2 and p300/CBP in signaling induced by interferon-α. Nature 1996;383:344-347.
11. Horwai AE, Xu L, Korzus E, Brard G, Kalafus D, Mullen TM, Rose DW, et al. Nuclear integration of Jak/Stat and Ras/AP-1 signaling by CBP and p300. Proc Natl Acad Sci U S A 1997;94:1074-1079.
12. Flati V, Haque SJ, Williams BRG. Interferon-α induced phosphorylation and activation of cyosolic phospholipase A2 is required for the formation of interferon-stimulated gene factor three. EMBO J 1996;15:1566-1571.
13. Piomelli D, Greengard R Lipoxygenase metabolites of arachidonic acid in neuronal transmembrane signaling. TIPS 1990;11:367-373.
14. Hii CS, Ferrante A, Egwards YS, Yuang ZH, Hartfield PJ, Rathjen DA, Poulos A, et al. Activation of mitogen-activated protein kinase by arachidonic acid in rat liver epithelial WB cells by a protein kinase C-dependent mechanism. J Biol Chem 1995;270:4201-4204.
15. Wen Z, Zhong Z, Darnell JE Jr. Maximal activation of transcription by STAT1 and STAT3 requires both tyrosine and serine phosphorylation. Cell 1995;82:241-251.
16. Fukuda R, Ishimura N, Kushiyama Y, Moriyama N, Ishihara S, Nagasawa S, Miyake T, et al. Effectiveness of interferon-alpha therapy in chronic hepatitis C is associated with the amount of interferon-alpha receptor mRNA in the liver. J Hepatol 1997;26:455-461.
17. Yatsuhashi H, Yamasaki K, Aritomi T, Carmen PM, Inoue O, Koga M, Yano M. Quantitative analysis of Interferon α/β receptor mRNA in the liver of patients with chronic hepatitis C: correlation with serum hepatitis C virus-RNA levels and response to tratment with Interferon. J Gastroenterol Hepatol 1997;12:460-467.
18. Morita T, Tanaka K, Saito S, Kitamura T, Kondo M, Sakaguchi T, Marimoto M, et al. Expression of interferon receptor genes (IFNα-R1 and IFNα-R2 mRNA) in the liver may predict outcome after interferon therapy in patients with chronic genotype 2a or 2b hepatitis C virus infection. J Clin Gastroenterol 1998;26:135-140.
19. Gale MJ, Korth MJ, Tang NM, Tan S, Hopkins DA, Dever TE, Polyak SJ, et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997;230:217-227.
20. Larner AC, Chauduri A, Darnell JR Jr. Transcriptional induction by interferon. J Biol Chem 1986;261:453-459.
21. Costantinescu SN, Croze E, Wang C, Murti A, Basu L, Mullersman JE, Pfeffer LM. Role of interferon-alpha/beta receptor chain-1 in the structure and transmembrane signaling of the interferon-alpha/beta receptor complex. Proc Natl Acad Sci U S A 1994;91:9602-9606.
22. Haspel RL, Salditt-Georgieff M, Darnell JE Jr. The rapid inactivation of nuclear tyrosine phosphorylated depends on a protein tyrosine phosphatase. EMBO J 1996;15:6262-6268.
23. Lee C-K, Bluyssen AR, Levy DE. Regulation if Interferon-α responsiveness by the duration of Janus kinase activity. J Biol Chem 1997;272:21872-21877.
24. Hannigan GE, Williams BRG. Signal transduction by interferon-α through arachidonic acid metabolism. Science 1991;251:204-207.
25. Anderson FH, Zeng L, Yoshida EM, Rock NR. Failure of ketoprofen and interferon combination therapy to improve interferon-resistant chronic hepatitis C. CanJ Gastroenterol 1997;11:294-297.
26. Zarski JP, Maynard-Muet M, Chousterman S, Baud M, Barnoud R, Abergel A, Bacq Y. et al. Tenoxicam, a non-steroid anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha interferon. HEPATOLOGY 1998;27:862-867.